Why the CSL (ASX:CSL) share price might be headed for more trouble

The CSL Limited (ASX: CSL) share price continues to drift nowhere. Can investors expect the ex-market darling to return to form?

| More on:
A doctor looks unsure, indicating share price uncertainty for ASX medical companies

Image source: Getty images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price has continued to trade sideways despite the S&P/ASX 200 Index (ASX: XJO) running around 6% higher year to date. 

The ASX 200 is now within 2% of its pre-COVID high, but the CSL share price needs to add another 25% to be in a similar position. After what seemed like strong half-year results back in February, what's next for the CSL share price? 

CSL share price impacted by plasma collections

Plasma is an essential raw material for CSL Behring's immunoglobulins, which generated US$4,256 million of the group's US$5,739 million revenue in the first half of FY21.

The pandemic has adversely affected plasma collections, with December 2020 collection volumes representing ~80% of December 2019 volumes. Plasma collections are arguably a factor that could sink or swim the CSL share price in the near term. 

The looming shortage has even seen the company turn to the public for ideas on how to get the community to step up plasma donations. CSL is offering $40,000 and mentorship as a reward for the winning idea. 

What does the broker say?

A note from Macquarie on 26 March observed that foot traffic across approximately 100 of CSL's US-based plasma collection centres had fallen below levels recorded in July-December 2020. 

In this note, the broker acknowledged that seasonality tended to play a role in the weakness experienced across late February and early March. Often associated with the timing of annual tax returns.

Moving through this period, the broker expected collections to improve from mid-March through to June. With these assumptions in mind, it retained a neutral rating for the CSL share price with a $288 target price. 

On Monday, Macquarie provided an update highlighting that collection centre foot traffic had yet to show a sustained improvement. The broker observes that foot traffic within the centres had eased in April after declines from mid-March. 

Without the anticipated improvement in plasma collections, Macquarie now expects lower immunoglobulin related revenue growth in FY22. 

The broker retained its neutral rating and lowered its target price from $288 to $282.50. This represents an upside of 5%, but the pressure is on CSL to lift its plasma collections. 

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Kerry Sun has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »

A man looking at his laptop and thinking.
Healthcare Shares

Should you buy the dip in the ResMed share price?

Let's see what one leading broker is saying following yesterday's pullback.

Read more »

A woman puts up her hands and looks confused while sitting at her computer.
Healthcare Shares

Down 5%: What's going on with the ResMed share price?

Let's see what has spooked investors today and caused them to push the sell button.

Read more »

Beautiful young woman drinking fresh orange juice in kitchen.
Healthcare Shares

Guess which ASX 300 stock is jumping 11% on big news

This stock is having a day to remember on Thursday. But why?

Read more »

A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
Healthcare Shares

Trump executive order to hit these 3 ASX pharmaceutical stocks

Donald Trump’s new executive order caused these 3 ASX pharmaceutical stocks to crash on Monday.

Read more »